Skip to main
ICUI

ICU Medical (ICUI) Stock Forecast & Price Target

ICU Medical (ICUI) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ICU Medical is well-positioned in the IV therapy market with its comprehensive portfolio and recent acquisitions of Hospira Infusion Systems and Smiths Medical. The company has reported solid revenue growth, margin expansion, and strong free cash flow in the second quarter of 2026 and has raised its guidance for the full year. Potential upside drivers include a pump upgrade cycle, market share gains, new product launches, improved pricing, and divestitures of slower growth products. Risks include gross margin pressure, regulatory challenges, and supply chain disruptions. Based on its current financial performance and potential for future growth, we maintain a Buy rating and a price target of $200 per share for ICU Medical stocks.

Bears say

ICU Medical is facing headwinds from the wind-down of an international OEM relationship, which will continue to weigh on its growth through the end of the year. Despite this, the company expects to sustain organic growth at or above 6%. However, our negative outlook is primarily driven by the company's high valuation, with a P/E multiple of 20.0x our 2027E adjusted EPS estimate. Additionally, there are potential risks to our rating and price target, including inconsistent commercial execution, competition, and geopolitical instability.

ICU Medical (ICUI) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICU Medical (ICUI) Forecast

Analysts have given ICU Medical (ICUI) a Buy based on their latest research and market trends.

According to 4 analysts, ICU Medical (ICUI) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $191, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $191, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICU Medical (ICUI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.